Boehringer awarded FDA Commissioner’s National Priority Voucher for HERNEXEOS® in HER2 lung cancer
Boehringer recently reported positive results from the Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced NSCLC at ESMO 2025. The company is pursuing regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback